SewellC.M., ClarridgeJ., LackeC., WeinmanE.J., YoungE.J.Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients.JAMA1982; 12: 1493–5.
2.
LuzarM.A., ColesG.A., FallerB.Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis.New Engl J Med1990; 322: 505–9.
3.
LyeW.C., LeongS.O., van der StraatenJ., LeeE.J.C.Staphylococcus aureus CAPD-related infections are associated with nasal carriage. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1994; 10: 163–5.
4.
PirainoB., PerlmutterJ.A., HolleyJ.L., BernardiniJ.Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients.Perit Dial Int1993; 13(Suppl 2): S332–4.
5.
ZimmermanS.W., AhrensE., JohnsonC.A.Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections.Am J Kidney Dis1991; 18: 225–31.
6.
BernardiniJ., LutesR., JohnstonJ.R., HolleyJ.L., PirainoB.Randomized trial of rifampin versus mupirocin to prevent S. aureus infections in PD patients (Abstract).Perit Dial Int1995; 15(Suppl): S17.
7.
Perez-FontanM., Garcia-FalconT., RosalesM.Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results.Am J Kidney Dis1993; 22: 708–12.
8.
ColesGA for the Mupirocin Study Group. The effect of intra-nasal mupirocin on CAPD exit site infections (Abstract).J Am Soc Nephrol1994; 5: 439.
